It was found that the expression level of DRD2 was increased in pancreatic cancer patients and that DRD2 inhibitors could slow tumour growth by inhibiting the extracellular regulated kinase (ERK) signalling pathway.75, 76. This evidence concerns the gene DRD2 and pancreatic neoplasm.